Terry RD, Davies P.: Dementia of the Alzheimer type. Ann Rev Neurosci1980;3:77-95.
2.
Davies P.: Neurotransmitter-related enzymes in senile dementia of the Alzheimer type . Brain Res1979;171:319-327.
3.
Cross AJ, Crow TJ, Perry EK, et al: Reduced dopamine betahydroxylase activity in Alzheimer's disease . Br Med J1981;282:93-94.
4.
Perry EK, Tomlinson BE, Blessed G., et al: Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J1978;2:1457-1459.
5.
Albert MA: Treating memory disorders in the elderly. Drug Ther1983;10:257-265.
6.
Jenike MA, Albert MS, Heller H., et al: Combination lecithin and Hydergine in the treatment of Alzheimer's disease. J Clin Psychiatry1986;47:249-251.
7.
Thal L., Masur D., Fuld P.: Memory improvement with oral physostigmine and lecithin in Alzheimer's disease , in Katzman R (ed): Banbury Report 15: Biological Aspects of Alzheimer's Disease. New York, Cold Spring Harbor Laboratory, 1983, pp 461-469.
8.
Mohs RC, Davis BM, Johns CA, et al: Oral physostigmine treatment of patients with Alzheimer's disease . Am J Psychiatry1985;142:28-33.
9.
Davis KL, Mohs RC, Rosen WG: Memory enhancement with oral physostigmine in Alzheimer's disease. N Engl J Med1983;308:721.
10.
Smith C., Swash M.: Physostigmine in Alzheimer's disease. Lancet1979;1:42.
11.
Jenike MA, Albert MS, Heller H., et al: Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: A double-blind placebo-controlled trial. J Clin Psychiatry1990;51:3-7.
12.
Jenike MA, Albert MS, Baer L.: Oral physostigmine as treatment for Alzheimer disease: A long-term outpatient trial. Alzheimer Dis Assoc Dis (in press).
13.
Davis KL, Mohs RC, Tinklenberg JR: Enhancement of memory by physostigmine. N Engl J Med1979;10:946.
14.
Christie JE , Shering A., Ferguson J., et al: Physostigmine and arecholine: Effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry1981;138:46-50.
15.
Davis KL, Mohs RC: Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry1982;139:1421-1424.
16.
Muramoto O. , Sugishita M., Sugita H., et al: Effect of physostigmine on constructional and memory tasks in Alzheimer's disease. Arch Neurol1979;36:501-501.
17.
Peters BH, Levin HS: Effects of physostigmine and lecithin on memory in Alzheimer disease. Ann Neurol1979;6:219-221.
18.
Denber Hcb: Physostigmine in the treatment of memory disorders: A case report. Psychiatr J Univ Ottawa1982;7:8-12.
19.
Mohs RC, Davis KL: A signal detectability analysis of the effect of physostigmine on memory in patients with Alzheimer's disease. Neurobiol Aging1982;3:105-110.
20.
Thal LJ, Fuld PA: Memory enhancement with oral physostigmine in Alzheimer's disease. N Engl J Med1983;6:720.
21.
Wettstein A. : No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease. Ann Neurol1983;13:210- 212.
22.
Ashford W., Soldinger S., Schaeffer I., et al: Physostigmine and its effect on six patients with dementia. Am J Psychiatry1981;138:829-830.
23.
Caltagirone C., Gainotti G., Masullo C.: Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia. Int J Neurosci1982;16:247-249.
24.
Delwaide PJ , Devoitille JM, Ylieff M.: Acute effect of drugs upon memory of patients with senile dementia. Acta Psychiatr Belg1980;80:748-754.
25.
McKhann G., Drachman D., Folstein M., et al: Clinical diagnosis of Alzheimers disease: Report of NINCDS-ADRDA workshop under the auspices of the Department of Health and Human Services Task Force. Neurology1984;34:939-944.
26.
Hachinski VC, Iliff LD, Zilhka E., et al: Cerebral blood flow in dementia. Arch Neurol1974;32:632-637.
27.
Mattis S.: Dementia Rating Scale, in Bellack R, Karasu B (eds): Geriatric Psychiatry. New York, Grune & Stratton, 1976.
28.
Jenike MA, Albert MS: The dexamethasone suppression test in patients with presenile and senile dementia of the Alzheimer's type. J Am Geriatr Soc1984;32:441-444.
29.
Kaplan E., Goodglass H., Weintraub S.: The Boston Naming Test. Philadelphia, Lea & Febiger, 1983.
30.
Buschke H., Fuld PA: Evaluating storage, retention and retrieval in disordered memory and learning . Neurology1974;24:1019-1026.
31.
Mohs RC, Rosen WG, Davis KL: The Alzheimer's Disease Assessment Scale (ADAS): An instrument for assessing treatment efficacy. Psychopharmacol Bull1983 ;19:448-450.
32.
Cohen J.: Statistical Power Analysis for the Behavioral Sciences, 2nd edition. Hillsdale, NJ, Lawrence Erlbaum, 1988.
33.
Bowen DM, Allen SJ, Benton JS, et al: Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem1983;41:266-272.
34.
Mann Dma, Yates PO, Hawkes J.: The noradrenergic system in Alzheimer and multi-infarct dementias. J Neurol Neurosurg Psychiatry1982;45:113-119.
35.
Gottfries CG , Adolfsson R., Aquilonius SM, et al: Biochemical changes in dementia disorders of Alzheimer's type (AD/ SDAT). Neurobiol Aging1983;4:261-271.
36.
Gottfries CG , Gottfries I., Roos BE: Homovanillic acid and 5-hydroxyindolacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism. J Neurochem1969 ;16:1341-1345.
37.
Gottfries CG , Gottfries I., Roos BE: The investigation of homovanillic acid in the human brain and its correlation to senile dementia. Br J Psychiatry1969;115:563-574.
